The haemodynamic effects of ketanserin were studied consecutively in seventeen patients in the intensive care unit following coronary artery bypass grafting. Hypertensive patients (Group 1. systolic blood pressure (SBP) ~ 150 mmHgfollowingdiscontinuation of nitroprusside. n = 10) received intravenous ketanserin 10 mg and infusion of 0.1 mgkg-I.hr-1 with additional boluses as required to maintain SBP ~ 130 mmHgfor one hour. Non-hypertensive patients (Group 2. SBP < 150 mmHg. n = 7) received a 5 mg bolus and the same infusion. Ketanserin significantly decreased arterial blood pressure (P < 0.001) in all patients in Group 1. Heart rate was decreased but not significantly. Cardiac index. systemic and pulmonary vascular resistance and pulmonary shunt fraction were not significantly altered from pre-ketanserin values when blood pressure was controlled with nitroprusside. Normotensive patients in Group 2 did not show any undesirable hypotension or significant haemodynamic changes. Mean nitroprusside dose requirements following ketanserin therapy were significantly reduced by 91.6% in Group 1 and 78.4% in Group 2 (P < 0.05). Ketanserin is effective in treating hypertension following coronary artery bypass grafting with an advantage of lack of reflex tachycardia.
intensive care unit because of its rapid onset of action and easy titratability. However it is often associated with reflex tachycardia and rebound hypertension. Ketanserin is a selective Srserotonergic antagonist with additional weak ai-adrenergic and HI-histaminergic blocking properties. It is therefore an appropriate drug to use to counteract hypertension pharmacologically in the post cardiac bypass period that may be caused by increased serotonin levels and to a smaller extent a-adrenergic activity. However, the mechanism of its antihypertensive effect remains imperfectly understood. It cannot be explained by Srserotonergic or ai-adrenergic blockade alone but an interaction between the two effects appears to be required. 7 ,8 It has been used to control blood pressure in a wide variety of clinical situations including perioperative hypertension in patients undergoing CABG, although an optimum dose has not been determined. 7 • 13 In two previous studies, ketanserin was not effective in controlling post CABG hypertension in about 15% of patients. 9 ,12 The usual recommended dose of an intravenous bolus of 10 mg or 0.15 mg.kg -I followed by infusion of 4-6 mg.hour -I was used. Higher doses than these have been used to treat patients with severe uncontrolled hypertension l4 - 16 and those developing hypertension during cardiopulmonary bypass. 10 It was therefore considered possible t~at ketanserin might control post CABG hypertensIOn more effectively if doses were titrated, instead of using a fixed dose regimen.
The aim of this study was to determine the haemodynamic effects and effectiveness of ketanserin as a substitute antihypertensive agent for sodium nitroprusside in the intensive care unit for patients who develop post CABG hypertension.
MATERIALS AND METHODS
Patients from 30 to 70 years of age and 40 to 100 kg in weight who had good ventricular function as assessed by the left ventricular end diastolic pressure (LVEDP less than 18 mmHg) and ventriculogram and were undergoing elective CABG were considered eligible for inclusion in the study. Patients with hypokalaemia < 3.5 mmol.l-1, severe bradycardia, postoperative blood loss of > 300 ml in the first two hours and patients with severe hepatic, renal or respiratory diseases were excluded from the study. Informed consent was obtained from all patients and this study was approved by the ethics committee of the hospital.
Preoperative medications ( Table 1) were continued till the night before surgery except for nitrates which were given along with premedication which consisted of intramuscular morphine 0.15 mg.kg -1 and hyoscine 0.2-0.4 mg given one hour prior to induction of anaesthesia.
All patients had a radial intra-arterial cannula and a pulmonary artery thermodilution catheter inserted prior to the induction of anaesthesia. The anaesthetic technique and drugs used varied between individual anaesthetists but this basically consisted of an opioid/nitrous oxide/ benzodiazepine anaesthetic. Vasodilator therapy, ie, glyceryl trinitrate (GTN) and sodium nitroprusside (SNP) infusions were also added as when required for controlling intraoperative hypertension.
All patients came off cardiopulmonary bypass uneventfully and did not require any inotropic support. They were transferred to the cardiothoracic intensive care unit and within half an hour of arrival, given intravenous diazepam 10 mg, pancuronium 4 mg and a morphine infusion of 1 mg.hr -1. They were all maintained on a GTN infusion of 1 Ilg.kg -1 .min -1 to ensure adequate distal and collateral coronary blood flow. SNP infusion (diluted to 0.2 mg.ml-1 ) was also continued when required to control the systolic blood pressure (SBP) at or below 130 mmHg.
The patients were stabilised in the intensive care unit for two hours following admission to ensure adequate ventilation, oxygenation, sedation, analgesia and flu~d replacement. At the end of two hours, SNP infusion was stopped and the blood pressure continuously observed at the patient's bedside. Two groups of patients were identified and studied.
Group 1 (n = 10): Patients with SBP ~ 150 mmHg within 15 minutes following discontinuation of SNP were given an intravenous bolus of ketanserin 10 mg diluted in 10 ml of saline over two minutes and started on an infusion of 0.1 mg.kg -1.hr -1. Intermittent boluses ofketanserin 5 mg were also given to maintain SBP ~ 130 mmHg at five-minute intervals when required. Group 2 (n = 7): Patients with SBP < 150 mmHg for 15 minutes after SNP was stopped were given an intravenous bolus of ketanserin 5 mg and also started on an infusion of 0.1 mg.kg -l.hr - 1. Ketanserin therapy was discontinued at the end of one hour after which SNP infusion was restarted when required to maintain SBP ::;; 130 mmHg.
The following haemodynamic parameters were measured: arterial blood pressure (BP) (systolic, diastolic and mean), pulmonary artery pressure (PAP) (systolic, diastolic and mean) and heart rate (HR). These were recorded before the administration ofketanserin (after discontinuation of SNP just before ketanserin was given), and at 5, 10, 15, 30, 60 and 180 minutes after the initial bolus of ketanserin. The following calculated indices were also measured using the Hemopro 1 Hemodynamic Profile Computer (Spectramed): cardiac index (Cl), systemic vascular resistance (SVR), pulmonary vascular resistance (PVR), and shunt fraction (Qs/Qt). These indices were recorded before ketanserin administration (prior to discontinuation of SNP infusion) and at 15,45 and 180 minutes after ketanserin. We also compared the dose requirements of SNP for the two hours before ketanserin administration and two hours after ketanserin in both groups.
One way analysis of variance (ANOVA) was used to analyse the means of all the haemodynamic parameters and a P value of < 0.05 was accepted as statistically significant. All results were expressed as a sequence of the means ± SD unless otherwise stated. Student's t-test was used to analyse the demographic data.
RESULTS
Seventeen patients were studied consecutively: ten patients in Group 1 and seven patients in Group 2. The age, sex, body surface area distributions and total cardiopulmonary bypass time were comparable in both groups ( Table 2) . Results of haemodynamic parameters before and after ketanserin are summarised in Tables 3 and 4 .
Arterial blood pressure
There were significant decreases of systolic BP (Figure 1) . None of the patients in Group 2 required any additional ketanserin to control the BP during the study period.
Pulmonary artery pressure
The systolic PAP decreased significantly (P < 0.05) in Group 1 following ketanserin therapy. There was also a decrease in the mean and diastolic PAP but this was not statistically significant. No significant changes in systolic, mean and diastolic PAP were observed in Group 2 ( Figure 2 ).
Heart Rate
There was a decrease in HR in Group 1 although this was not statistically significant. No significant· 40, DJ .r:: difference in HR was observed in Group 2 ( Figure  3 ). No arrythmias were noted during the period of study.
Cl, SVR, PVR and QsIQt
These were not significantly different from preketanserin values following ketanserin therapy in both Groups 1 and 2 (Figure 4 ).
Ketanserin Dose
The mean total dose ofketanserin used in Group 1 was 46.3 ± 16.1 mg and 10.9 ± 5 mg in Group 2.
Nitroprusside requirements
There was a significant 91.6% decrease in SNP requirements from 55.9 ± 37.6 ml.hour-I preketanserin to 4.7 ± 4.2 ml.hour -I post-ketanserin in Group 1 (P < 0.05). Group 2 also showed a significant decrease of 78.4% from 9.7 ± 6.0 ml.hour -I to 2.1 ± 2.4 ml.hour -I. .0 (l) ..., 
DISCUSSION
This study showed that ketanserin is effective in controlling hypertension developing in patients following coronary artery bypass surgery. Ketanserin also prevented the rebound hypertension that occurred following the discontinuation of nitroprusside therapy. In all ten patients in Group 1, a 10 mg bolus of ketanserin was immediately effective in lowering the systolic blood pressure within the first five minutes. We were also able to maintain the systolic blood pressure at around 130 mmHg for the next hour but this was achieved only with additional intermittent bolus doses of ketanserin. No rebound hypertension was noted following the discontinuation of ketanserin therapy. A mean total dose of 46.3 ± 16.1 mg was given during the one hour of ketanserin therapy. This is similar to the dosage of ketanserin used to treat patients with severe uncontrolled hypertension (between 30 to 50 mg)14-16 and patients who develop hypertension during cardiopulmonary bypass (0.466 ± 0.343 mg.kg -1 ).10 This dose is much higher than that used in two studies where a 10 mg or 0.15 mg.kg -1 bolus dose followed by an infusion of 4 to 6 mg.hr-1 respectively was used to treat post CABG hypertension. 8 ,12 This difference in dose requirements may be due to differences in our patient population or the type and dose of anaesthetic used during surgery. In the above two studies, ketanserin alone was ineffective in controlling hypertension in seven out of forty and eleven out of thirteen patients respectively.8,121t is possible that these patients could have responded if higher doses of ketanserin were given. It must be noted though that the use of nitroglycerin infusion (mean values ± SEM). at 1 Jlg.kg -I.min -I in our patients could have also contributed to the ease of controlling their blood pressure.
There was no statistically significant change in the heart rate in this group of patients. This lack of reflex tachycardia in response to the hypotensive effect of ketanserin has been documented in previous studies. 9 • 13 The mechanism of its effect on heart rate is unclear but prolongation of QT interval or a-adrenergic-blockade-mediated sympathetic inhibition have been postulated. 7 Our pre-ketanserin measurements of cardiac index, systemic and pulmonary vascular resistance and pulmonary shunt fraction were performed while the blood pressure of the patients was still controlled with nitroprusside infusion, since the authors felt that it was not justified to turn off nitroprusside because of the time required to obtain these measurements. No statistically significant change in these indices occurred when blood pressure control was switched from nitroprusside to ketanserin therapy.
The significant decrease in the dose of nitroprusside required to control the blood pressure in the two-hour pre-ketanserin and the two-hour post-ketanserin period may be due to several factors. Some investigators have reported that post-revascularization hypertension is paroxysmal, subsiding in four to six hours whether or not the patient is treated. 6 Others however believe that the duration of hypertension is longer. 2 The elimination half-life of an intravenous dose of ketanserin of 0.1 5 mg.kg -I or 10 mg has been calculated to be between 12.8 ± 4.8 and 14.3 ± 4.4 hours. 17 ,18 The marked decrease in nitroprusside requirements in the post-ketanserin period could therefore be due to the higher dose of ketanserin used in our patients resulting in a more prolonged hypotensive effect. In a double-blind, placebo controlled study, ketanserin at various infusion rates was administered to patients who developed hypertension following coronary artery bypass surgery with sodium nitroprusside as escape medication. 13 The effects of ketanserin were found to be additive and ketanserin infusion resulted in a reduced duration and volume of nitroprusside infusion. Sedation and somnolence, which were reported in 18 out of 20 severely hypertensive patients who received a mean intravenous dose of between 28 and 38 mg of ketanserin, could also have contributed to a decrease in blood pressure and hence nitroprusside requirements. 16 This reduction in nitroprussioe requirements in hypertensive patients following ketanserin therapy suggests that it could alternatively be used in smaller doses as an adjunct to nitroprusside in controlling post coronary artery bypass grafting hypertension. This would reduce the risk of cyanide toxicity arising from high infusion rates of nitroprusside.
Patients in Group 2 did not develop hypertension (as defined by systolic blood pressure > 150 mmHg). In normotensive healthy volunteers, intravenous treatment with ketanserin has little or no effect on blood pressure in contrast to hypertensive patients. 8 We decided to investigate the haemodynamic effects of a 5 mg bolus of ketanserin followed by the same infusion rate of 0.1 mg.kg -I.hr -I in these patients. There were no significant or adverse changes in all the haemodynamic parameters although there was a slight decrease in the arterial blood pressure after the initial 5 mg bolus dose.
In conclusion, ketanserin was effective in controlling the blood pressure in patients who develop hypertension following coronary artery bypass grafting. There was no reflex tachycardia following its hypotensive effect or rebound hypertension after its discontinuance. The absence of these side-effects makes it a possible alternative to sodium nitroprusside as a hypotensive agent in this group of patients. A wide range of doses which were much higher than the recommended therapeutic doses were used in our patients. No adverse haemodynamic sequelae resulted from the use of these high doses. We therefore suggest that dosage should perhaps be titrated to individual requirements.
